Enhancing Provider Education on the Concomitant Use of Psychedelic Substances and Psychotropic Medications

Abstract

Purpose: The purpose of this project was to enhance provider knowledge of the clinical considerations involved in the concurrent use of psychedelic substances and psychotropic medications and promote patient-centered harm reduction strategies. Background: Limited knowledge existed about drug-drug interactions between psychedelics and psychotropic medications, despite both influencing similar neurotransmitters and metabolic pathways. This project focused on three substances—lysergic acid diethylamide (LSD), psilocybin, and methylenedioxymethamphetamine (MDMA). Additionally, stigma associated with psychedelic use often prevents patients from disclosing non-clinical substance use. Incorporating a harm-reduction framework in clinical practice encourages open communication, supporting patient autonomy, enhancing safety, and improving treatment outcomes. Methods: This project was part of a quality improvement initiative that included an educational session designed to increase provider knowledge, attitudes, and motivation. The session, delivered via a prerecorded presentation, covered the pharmacological interactions between psychedelics and psychotropic medications, common adverse effects, and harm-reduction strategies. Pre- and post-surveys assessed the intervention’s effectiveness. Results: Limited participation and a small sample size (n = 1) impacted the statistical significance and generalizability of the findings. However, survey results indicated that the intervention partially improved provider knowledge and confidence in discussing psychedelics, although some knowledge gaps persisted. The provider demonstrated high motivation throughout, suggesting sustained engagement to support future learning. Expanding participation and addressing specific gaps were recommended to refine the intervention and increase its impact. Conclusions: This project underscored the importance of provider education on the interactions between psychedelic substances and psychotropic medications to enhance patient safety and improve harm reduction efforts. While initial results showed that targeted education boosted knowledge and confidence, greater participation is essential to validate these findings. Expanding research and integrating psychedelic education into mental health practice will be key to advancing clinical care and optimizing patient outcomes in this emerging area.